TORONTO, Nov. 6, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that at the recent American Osteopathic Association ("AOA") 111th Annual Convention and Scientific Seminar in Las Vegas, Swiss Medica's exclusive professional market distributor, North American Physicians Inc. ("NAPI"), generated significant interest for Swiss Medica's products (O24 Pain Neutralizer, O24 Fibromyalgia and PMS Escape) from the American Osteopathic medical community.
Sam Halim, CEO of NAPI noted "The success at this show in terms of sampling, sales of product to medical professionals for resale and general interest in our products is truly indicative of the huge potential we see in the distribution of Swiss Medica's patented, clinically-tested products within the medical community."
At the convention, Dr. Sprague Taveau presented a Continuing Medical Education ("CME") seminar to a packed room on the "Diagnosis and Treatment of Fibromyalgia and Chronic Fatigue Syndrome" in which he recommended O24 Fibromyalgia as part of his fibromyalgia treatment methodology. Dr Taveau stated: "Based on the study I conducted using Swiss Medica's O24 Fibromyalgia product, I found that my patients responded extremely well to the product. O24 Fibromyalgia is the only topical pain relief I recommend to my patients who suffer from fibromyalgia and chronic fatigue."
At the same conference Dr. Joseph Lillo presented a CME entitled "Diagnosis and Treatment of Osteoarthritis" in which he recommended O24 Pain Neutralizer as part of his treatment methodology.
About North American Physicians Inc.
North American Physicians Inc. ("NAPI") is a Boca Raton, Florida-based Company that distributes all-natural, over-the-counter medically/clinically tested products into the United States healthcare market. NAPI sells its exclusive line of products to physician offices/kiosks, pain management clinics, hospitals, therapy centers, short and long-term care facilities, and chiropractor and podiatry clinics. NAPI exclusively distributes to the professional community: O24 Pain Neutralizer, O24 Fibromyalgia and PMS Escape.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds U.S. Patent No. 6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launched the patented O24 Fibromyalgia pain reliever (U.S. Patent No. 6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 percent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 percent who used the placebo. Customers can also visit www.O24zone.com for ordering details and store locators for the nearest retailer.
Swiss Medica also distributes PMS Escape which holds U.S. Patent Nos. 5760014 and 5612320. PMS Escape is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.